sulfotransferase family 2B member 1Genealiases: ARCI14 · HSST2
Q-omics provides the consensus-scored SULT2B1 profile across patient tissues and cancer cell-line models. SULT2B1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, SULT2B1 is differentially expressed in 16, with the highest sampling consensus in COAD. Additionally, SULT2B1 protein abundance shows 20,872 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRC, COAD, and HNSC as cancer lineages where SULT2B1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SULT2B1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SULT2B1 survival associations across molecular data types. SULT2B1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SULT2B1 RNA expression–survival associations across cancer types. High SULT2B1 expression shows unfavorable associations in KIRC, LUAD, UVM, ACC, COAD and SKCM. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for SULT2B1 RNA expression.
This table summarizes SULT2B1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 9. The strongest signals are observed in COAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for SULT2B1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SULT2B1 shows lower tumor expression in KIRC and KICH and higher tumor expression in COAD, THCA, READ and UCEC. The COAD box plot shows higher SULT2B1 RNA expression in tumor versus normal tissue (log2 FC = +4.144, t-test p < 0.001).
This table shows molecular features associated with SULT2B1 in patient tissues and cancer cell lines. In patient samples, SULT2B1 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, SULT2B1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and BREAST.
